Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Eagle Pharmaceuticals excels in 2022 with strong earnings growth

Eagle Pharmaceuticals' 2022 performance reflects strong earnings growth and operational efficiency, supported by key product sales and financial stability.
While facing challenges in managing expenses amidst investments, the company's strategic strengths lie in its product portfolio and financial resilience.
Opportunities for revenue growth and market expansion present avenues for Eagle Pharmaceuticals to further enhance its competitive position and drive future success.

Eagle Pharmaceuticals posts robust Q1 results, eyes strategic growth opportunities

Eagle Pharmaceuticals delivered a strong financial performance in Q1 2023, driven by key product sales and market share retention.
While facing challenges in expenses management, the company's solid cash position and growth strategies position it well for future opportunities.
Strategic initiatives like potential acquisitions and market expansion underscore Eagle Pharmaceuticals' commitment to sustained growth and innovation.

Eagle Pharmaceuticals beats Q2 estimates, eyes growth through strategic investments

Eagle Pharmaceuticals delivered a robust Q2 performance, exceeding expectations and demonstrating strong financial health. The company's strategic investments in R&D and commercial infrastructure position it well for future growth. Despite challenges and uncertainties, Eagle Pharmaceuticals remains optimistic about its continued growth trajectory and market prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abstracts to be presented cover preclinical data on RYANODEX® (dantrolene sodium) for injectable suspension in Acute Radiation Syndrome and Traumatic Brain Injury Abstracts to be presented cover preclinical data on RYANODEX® (dantrolene sodium) for injectable suspension in Acute Radiation Syndrome and Traumatic Brain Injury

Eagle Pharmaceuticals Announces Acceptance of Two Abstracts at the Society for Academic Emergency Medicine (SAEM) Annual Meeting

Eagle Pharmaceuticals, Inc. (EGRX) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Corporate Participants Lisa Wilson - Investor Relations Scott Tarriff - President and Chief Executive Officer Brian Cahill - Chief Financial Officer Mike Greenberg - Vice President of Medical Affairs Conference Call Participants Lachlan Hanbury-Brown - William Blair Brandon Folkes - Cantor Fitzgerald David Amsellem - Piper Sandler Operator Good morning, everyone. My name is Todd and I'll be your conference operator.

Eagle Pharmaceuticals, Inc. (EGRX) Q1 2023 Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $4.04 per share a year ago.

Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Beat Estimates

WOODCLIFF LAKE, N.J., May 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three months ended March 31, 2023.

Eagle Pharmaceuticals Reports First Quarter 2023 Results

-- Byfavo1 is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®¹ (remimazolam for injection) from CMS

WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its first quarter 2023 financial results on Tuesday, May 9, 2023, before the market opens.

Eagle Pharmaceuticals to Host First Quarter 2023 Financial Results on May 9, 2023

WOODCLIFF LAKE, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, “Dr. Reddy's”). Eagle had asserted its Orange Book-listed patents against Dr. Reddy's related to its new drug application referencing BENDEKA®. Under the settlement agreement, Dr. Reddy's has the right to market its product beginning November 17, 2027, or earlier based on certain circumstances. The settlement agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. The settlement with Dr. Reddy's follows Eagle's previously announced settlements with Hospira, Inc. (“Hospira”) and Accord Healthcare, Inc. (“Accord”) related to their new drug applications referencing BENDEKA®.

Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Ltd. Related to BENDEKA® (bendamustine hydrochloride)

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX ) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - President and Chief Executive Officer Brian Cahill - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Lachlan Hanbury-Brown - William Blair David Amsellem - Piper Sandler Operator Good morning, everyone. My name is Todd, and I'll be your conference operator.

Eagle Pharmaceuticals, Inc. (EGRX) Q4 2022 Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates

• Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share1

Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

WOODCLIFF LAKE, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference, in Miami, FL, as follows:

Eagle Pharmaceuticals to Present at the Barclays Global Healthcare Conference

WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:

Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

WOODCLIFF LAKE, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023.

Eagle Pharmaceuticals Provides Business Update and Guidance for 2023

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?

WOODCLIFF LAKE, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference as follows:

Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

-- Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations -- -- Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma --

Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy

Are Investors Undervaluing Eagle Pharmaceuticals (EGRX) Right Now?

WOODCLIFF LAKE, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Accord Healthcare, Inc. (“Accord”). Eagle had asserted its Orange Book-listed patents against Accord related to Accord's new drug application (“NDA”) referencing BENDEKA®. The settlement agreement provides that Accord has the right to market its product beginning January 17, 2028, or earlier based on certain circumstances. The settlement agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Eagle Pharmaceuticals Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA® (bendamustine hydrochloride)

-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company's hospital-based products and pipeline programs: Enalare's ENA-001, CAL02, BARHEMSYS®, BYFAVO® and landiolol --

Eagle Pharmaceuticals' Investor Day to Focus on Acute Care Products and Pipeline Programs; Tuesday, December 6, 2022, at 8:00am ET at the Lotte New York Palace

Eagle Pharmaceuticals' Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

-- Expect to begin a Phase 2 study in approximately 276 patients with severe community-acquired pneumonia at approximately 120 sites worldwide -- -- Patient enrollment expected to commence as early as the beginning of 2023 --

Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

WOODCLIFF LAKE, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originally issued on November 7, 2022 at 6:50 am ET, to correct errors in the presentation of certain line items in the financial statements included therein and corresponding references to such items in the narrative disclosure as described in the Company's Form 8-K/A filed on November 9, 2022.  All other information in the earnings press release remains unchanged, including adjusted non-GAAP net income, adjusted non-GAAP basic and diluted earnings per share and adjusted non-GAAP EBITDA.

Correcting & Replacing: Eagle Pharmaceuticals Reports Third Quarter 2022 Results

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX ) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - President & Chief Executive Officer Brian Cahill - Chief Financial Officer Conference Call Participants Tim Lugo - William Blair Brandon Folkes - Cantor Fitzgerald David Amsellem - Piper Sandler Operator Good morning, everyone. My name is Todd and I'll be your conference operator.

Eagle Pharmaceuticals, Inc. (EGRX) Q3 2022 Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates

WOODCLIFF LAKE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2022.

News for Eagle Pharmaceuticals Stock (EGRX)